Bannerbild German Brest Group

May 2019: Long-term outcomes of the GeparSepto study


The long-term follow-up data of the phase III GeparSepto (GBG 69) study that aimed to compare weekly nab-paclitaxel with weekly sb-paclitaxel followed by epirubicin plus cyclophosphamide (EC) as neoadjuvant treatment in patients with primary breast cancer has been published in the Journal of Clinical Oncology.

Between July 30, 2012 and December 23, 2013 a total of 1,373 patients within 69 German sites were screened for eligibility of whom 1,229 were randomised. Of the 1,206 patients who started treatment 73.3% (444/606) randomised in the nab-paclitaxel arm and 79.5% (477/600) in the sb-paclitaxel arm completed the taxane and EC therapy. The pCR Pathological complete response (pCR=ypT0 ypN0) was significantly higher after nab-paclitaxel compared to sb-paclitaxel (38.4% vs 29.0%; OR=1.53 [95%CI 1.20-1.95]; unadjusted p<0.001) (Untch M. et al. Lancet Oncol 2016). After a median follow-up of 49.6 months (range 0.5-64.0 months), 243 invasive disease-free survival (iDFS) events were reported. The 4-year iDFS was significantly better in patients treated with nab-paclitaxel compared to sb-paclitaxel (84.0% vs 76.3%; HR=0.66 [95%CI 95%CI 0.51-0.86]; p=0.002), whereas overall survival did not significantly differ between the two treatment arms (89.7% vs 87.2%, respectively; HR=0.82 [95%CI 0.59-1.16]; p=0.260). These data demonstrated that the higher pCR rate translated into an improved iDFS after nab-paclitaxel compared to sb-paclitaxel treatment. Furthermore, long-term follow-up of the treatment-related peripheral sensory neuropathy (PSN) showed a significant decrease of the median time to resolve PSN after nab-paclitaxel 125 mg/m2 compared with nab-paclitaxel 150 mg/m2. Hence, the long-term results support the use of nab-paclitaxel 125 mg/m2 instead of sb-paclitaxel in patients with early BC.

Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol. 2019 May 13. [Epub ahead of print]


  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 15.11.2018 Save the Date: AGO-Mamma 2019

    Save the Date: AGO-Mamma 2019

    Das State-of-the-Art-Meeting 2019 der AGO Organkomission Mamma wird am 16. März 2019 in Frankfurt stattfinden.

    Mehr ...
  • 05.11.2018 October 2018: Long-term survival analysis of GeparSixto trial

    The survival analysis of patients with triple-negative and HER2-positive early breast cancer enrolled in the neoadjuvant GeparSixto (GBG 66) phase II trial have been published in the Annals of Oncology.

    Mehr ...
  • 15.10.2018 GBG Research at ESMO

    Data of several GBG trials and translational research projects will be presented at the upcoming ESMO 2018 Congress, which will take place from 19 to 23 October in Munich, Germany.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd